Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) $ in Millions			3 Months Ended		9 Months Ended		12 Months Ended	36 Months Ended
		Sep. 03, 2015	Oct. 02, 2016 USD ($)	Sep. 27, 2015 USD ($)	Oct. 02, 2016 USD ($) site	Sep. 27, 2015 USD ($)	Dec. 31, 2015 USD ($)	Sep. 03, 2018 USD ($)
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost			$ 3,000		$ 3,000
Total costs associated with acquisitions and cost-reduction/productivity initiatives					1,200
Restructuring charges:
Employee terminations	[1]		347	$ 241	464	$ 306
Asset impairments	[1]		27	198	45	209
Exit costs	[1]		29	30	64	40
Total restructuring charges	[1]		404	469	574	555
Transaction costs	[2]		54	64	114	70
Integration costs	[3]		74	48	300	102
Restructuring charges and certain acquisition-related costs	[4]		531	581	988	727
Total additional depreciation––asset restructuring	[5]		47	24	151	71
Implementation costs recorded in our condensed consolidated statements of income as follows:
Total implementation costs	[6]		78	42	202	135
Total costs associated with acquisitions and cost-reduction/productivity initiatives			655	647	1,341	933
Cost of Sales [Member]
Restructuring charges:
Total additional depreciation––asset restructuring	[5]		46	23	145	67
Implementation costs recorded in our condensed consolidated statements of income as follows:
Total implementation costs	[6]		46	23	127	64
Selling, Informational and Administrative Expenses [Member]
Implementation costs recorded in our condensed consolidated statements of income as follows:
Total implementation costs	[6]		23	16	56	55
Research and Development Expense [Member]
Restructuring charges:
Total additional depreciation––asset restructuring	[5]		1	1	5	3
Implementation costs recorded in our condensed consolidated statements of income as follows:
Total implementation costs	[6]		8	2	17	13
Other (Income)/Deductions - net [Member]
Implementation costs recorded in our condensed consolidated statements of income as follows:
Total implementation costs	[6]		1	2	$ 2	3
Manufacturing Plant Network Rationalization And Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Expected number of sites exited | site					7
Acquisition-related Costs [Member] | Manufacturing Plant Network Rationalization And Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost			400		$ 400
Restructuring costs incurred			365		365
Facility Closing [Member] | Manufacturing Plant Network Rationalization And Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost			1,100		1,100
Restructuring costs incurred			828		828
Business Restructuring Reserves [Member] | Global Commercial Structure Reorganization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred			219		219
Commercial Real Estate [Member] | Other Cost Reduction / Productivity Initiatives [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost			1,300		1,300
Restructuring costs incurred			$ 895		$ 895
Hospira [Member]
Restructuring Cost and Reserve [Line Items]
Expected integration related costs, period		3 years
Hospira [Member] | Return of Acquired Rights [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring cost incurred associated with the return of acquired in-process research and development rights				$ 205		$ 205	$ 215
Forecast [Member] | Hospira [Member]
Restructuring charges:
Integration costs								$ 1,000

[1] In the nine months ended October 2, 2016, Employee terminations represent the expected reduction of the workforce by approximately 2,100 employees, mainly in manufacturing, sales, research and corporate. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.The restructuring charges for 2016 are associated with the following:•For the third quarter of 2016, the IH segment ($148 million); the EH segment ($28 million); WRD, GPD and Medical (M) (WRD/GPD/M) ($52 million); manufacturing operations ($108 million); and Corporate ($67 million).•For the first nine months of 2016, IH ($162 million); EH ($19 million); WRD/GPD/M ($104 million); manufacturing operations ($181 million); and Corporate ($107 million).The restructuring charges for 2015 are associated with the following:•For the third quarter of 2015, IH ($9 million); EH ($280 million); WRD/GPD/M ($50 million); manufacturing operations ($26 million); and Corporate ($104 million).•For the first nine months of 2015, IH ($55 million); EH ($288 million); WRD/GPD/M ($66 million); manufacturing operations ($18 million); and Corporate ($127 million).In September 2015, in order to eliminate certain redundancies in Pfizer’s biosimilar drug products pipeline created as a result of the acquisition of Hospira, Pfizer opted to return rights to Celltrion that Hospira had previously acquired to potential biosimilars to Rituxan® (rituximab) and Herceptin® (trastuzumab). As such, upon return of the acquired rights, in the third quarter and first nine months of 2015, we incurred charges of $205 million, which are comprised of (i) a write-off of the applicable IPR&D assets, totaling $160 million, which is included in Asset impairments; (ii) a write-off of amounts prepaid to Celltrion in the amount of $25 million, which is included in Asset impairments; and (iii) a payment to Celltrion of $20 million, which is included in Exit costs.

[2] Transaction costs represent external costs for banking, legal, accounting and other similar services, most of which in the third quarter of 2016 are directly related to our acquisition of Medivation, and most of which in the first nine months of 2016 are directly related to our acquisitions of Medivation and Anacor, and the terminated transaction with Allergan. Transaction costs in 2015 represent external costs directly related to the acquisition of Hospira and primarily include expenditures for banking, legal, accounting and other similar services.

[3] Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In the third quarter of 2016, integration costs mostly relate to our acquisition of Hospira and for the first nine months of 2016, integration costs mostly relate to our acquisition of Hospira and the terminated transaction with Allergan. Integration costs in 2015 represent external incremental costs directly related to our acquisition of Hospira.

[4] Amounts may not add due to rounding.

[5] Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.

[6] Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.